Trial reportThe Journal of urology2019
Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.
Trial report in The Journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Trial
- Landmarks in the evolution of prostate biopsy.Nature reviews. Urology · 2023Review
- An Augmented Reality System with Advanced User Interfaces for Image-Guided Intervention Applications.Proceedings of SPIE--the International Society for Optical Engineering · 2023Article
- Virtual Navigator Real-Time Ultrasound Fusion Imaging with Positron Emission Tomography/Computed Tomography for Preoperative Breast Cancer.Medicina (Kaunas, Lithuania) · 2021Article
- Utility ofAJR. American journal of roentgenology · 2021Article
- Automatic Segmentation of the Prostate on MR Images based on Anatomy and Deep Learning.Proceedings of SPIE--the International Society for Optical Engineering · 2021Article
- Exploratory study ofAmerican journal of nuclear medicine and molecular imaging · 2021Article
- Understanding and ImprovingProstate cancer · 2020Review
- An Augmented Reality-Assisted Visualization System for Potential Applications in Prostate Biopsy.Proceedings of SPIE--the International Society for Optical EngineeringArticle
- Role of molecular imaging in the detection of localized prostate cancer.Therapeutic advances in urologyReview
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
purposeWe assessed the feasibility and cancer detection rate of fluciclovine ( MATERIALS AND
methodsA total of 21 patients with a mean ± SD prostate specific antigen of 7.4 ± 6.8 ng/ml and biochemical failure after nonoperative prostate cancer treatment underwent fluciclovine (
resultsTemplate biopsy was positive for malignancy in 6 of 21 patients (28.6%), including 10 of 124 regions and 11 of 246 cores, vs targeted biopsy in 10 of 21 (47.6%), including 17 of 50 regions and 40 of 125 cores. Five of 21 patients had positive findings on targeted biopsy only and 1 of 21 had positive findings on template biopsy only. An additional case was upgraded from Grade Group 2 to 3 on targeted biopsy. Extraprostatic disease was detected in 8 of 21 men (38.1%) with histological confirmation in all 3 who underwent lesion biopsy.
conclusionsFluciclovine positron emission tomography real-time ultrasound fusion guidance for biopsy is feasible in patients with biochemical failure after nonsurgical therapy for prostate cancer. It identifies more recurrent prostate cancer using fewer cores compared with template biopsy in the same patient. Further study is required to determine in what manner targeted biopsy may augment template biopsy of recurrent prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.